Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation

References

• RK Maheshwari, AK Singh, J Gaddipati, RC Srimal. Multiple biological activities of curcumin: A short review. Life Sci 2006;78:2081–2087.
   PubMed Web of Science ®Google Scholar
• K Balasubramanian. Molecular orbital basis for yellow curry spice curcumin's prevention of alzheimer's disease. J Agric Food Chem 2006;54:3512–3520.
   PubMed Web of Science ®Google Scholar
• F Payton, P Sandusky, WL Alworth. NMR study of the solution structure of curcumin. J Nat Prod 2007;70:143–146.
   PubMed Web of Science ®Google Scholar
• Y Fu, S Zheng, J Lin, J Ryerse, A Chen. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399–409.
   PubMed Web of Science ®Google Scholar
• K Kohli, J Ali, MJ Ansari, Z Raheman. Curcumin: A natural antiinflammatory agent. Indian J Pharmacol 2005;37:141–147.
   Google Scholar
• S Sharma, SK Kulkarni, K Chopra. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006;33:940–945.
   PubMed Web of Science ®Google Scholar
• T Nishiyama, T Mae, H Kishida, M Tsukagawa, Y Mimaki, M Kuroda, Y Sashida, K Takahashi, T Kawada, K Nakagawa, M Kitahara. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005;53:959–963.
   PubMed Web of Science ®Google Scholar
• OP Sharma. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976;25:1811–1812.
   PubMed Web of Science ®Google Scholar
• GS Sidhu, AK Singh, D Thaloor, KK Banaudha, GK Patnaik, RC Srimal, RK Maheshwari. Enhancement of wound healing by curcumin in animals. Wound Repair Regen 1998;6:167–177.
   PubMedGoogle Scholar
• PS Negi, GK Jayaprakasha, L Jagan Mohan Rao, KK Sakariah. Antibacterial activity of turmeric oil: A byproduct from curcumin manufacture. J Agric Food Chem 1999;47:4297–4300.
   PubMed Web of Science ®Google Scholar
• ME Egan, M Pearson, SA Weiner, V Rajendran, D Rubin, J Glockner-Pagel, S Canny, K Du, GL Lukacs, MJ Caplan. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600–602.
   PubMed Web of Science ®Google Scholar
• F Yang, GP Lim, AN Begum, OJ Ubeda, MR Simmons, SS Ambegaokar, PP Chen, R Kayed, CG Glabe, SA Frautschy, GM Cole. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892–5901.
   PubMed Web of Science ®Google Scholar
• S Mishra, K Karmodiya, N Surolia, A Surolia. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem 2008;16:2894–2902.
   PubMed Web of Science ®Google Scholar
• RA Sharma, AJ Gescher, WP Steward. Curcumin: The story so far. Eur J Cancer 2005;41:1955–1968.
   PubMed Web of Science ®Google Scholar
• G Kuttan, KB Kumar, C Guruvayoorappan, R Kuttan. Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 2007;595:173–184.
   PubMed Web of Science ®Google Scholar
• H Aoki, Y Takada, S Kondo, R Sawaya, BB Aggarwal, Y Kondo. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007;72:29–39.
   PubMed Web of Science ®Google Scholar
• CH Hsu, AL Cheng. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471–480.
   PubMed Web of Science ®Google Scholar
• N Dhillon, BB Aggarwal, R Newman, R Wolff, A Kunnumakkara, J Abbruzzese, D Hong, L Camacho, C Ng, C Kurzrock. Curcumin and pancreatic cancer: Phase II clinical trial experience. J Clin Oncol 2007;25 (18S):4599. ASCO Annual Meeting Proceedings
   Google Scholar
• AL Cheng, CH Hsu, JK Lin, MM Hsu, YF Ho, TS Shen, JY Ko, JT Lin, BR Lin, W Ming-Shiang, HS Yu, SH Jee, GS Chen, TM Chen, CA Chen, MK Lai, YS Pu, MH Pan, YJ Wang, CC Tsai, CY Hsieh. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895–2900.
   PubMed Web of Science ®Google Scholar
• K Balasubramanyam, RA Varier, M Altaf, V Swaminathan, NB Siddappa, U Ranga, TK Kundu. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163–51171.
   PubMed Web of Science ®Google Scholar
• T Morimoto, Y Sunagawa, T Kawamura, T Takaya, H Wada, A Nagasawa, M Komeda, M Fujita, A Shimatsu, T Kita, K Hasegawa. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008;118:868–878.
   PubMed Web of Science ®Google Scholar
• SM Plummer, KA Holloway, MM Manson, RJ Munks, A Kaptein, S Farrow, L Howells. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013–6020.
   PubMed Web of Science ®Google Scholar
• YP Lu, RL Chang, MT Huang, AH Conney. Inhibitory effect of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 1993;14:293–297.
   PubMed Web of Science ®Google Scholar
• TS Huang, SC Lee, JK Lin. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991;88:5292–5296.
   PubMed Web of Science ®Google Scholar
• S Singh, BB Aggarwal. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995–25000.
   PubMed Web of Science ®Google Scholar
• F Demarchi, C Bertoli, P Sandy, C Schneider. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003;278:39583–39590.
   PubMed Web of Science ®Google Scholar
• AC Bharti, N Donato, S Singh, BB Aggarwal. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053–1062.
   PubMed Web of Science ®Google Scholar
• N Embi, DB Rylatt, P Cohen. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519–527.
   PubMedGoogle Scholar
• A Martinez, A Castro, I Dorronsoro, M Alonso. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373–384.
   PubMed Web of Science ®Google Scholar
• I Dorronsoro, A Castro, A Martinez. Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs?. Expert Opin Ther Patents 2002;12:1527–1536.
   Web of Science ®Google Scholar
• M Alonso, A Martinez. GSK-3 inhibitors: Discoveries and developments. Curr Med Chem 2004;11:755–763.
   PubMed Web of Science ®Google Scholar
• MK Mohammad, IM Al-Masri, MO Taha, MA Al-Ghussein, HS Alkhatib, S Najjar, Y Bustanji. Olanzapine inhibits glycogen synthase kinase-3beta: An investigation by docking simulation and experimental validation. Eur J Pharmacol 2008;584:185–191.
   PubMed Web of Science ®Google Scholar
• MO Taha, Y Bustanji, MA Al-Ghussein, M Mohammad, H Zalloum, IM Al-Masri, N Atallah. Pharmacophore modeling, quantitative structure–activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 2008;51:2062–2077.
   PubMed Web of Science ®Google Scholar
• E Droucheau, A Primot, V Thomas, D Mattei, M Knockaert, C Richardson, P Sallicandro, P Alano, A Jafarshad, B Baratte, C Kunick, D Parzy, L Pearl, C Doerig, L Meijer. Plasmodium falciparum glycogen synthase kinase-3: Molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta 2004;1697:181–196.
   PubMed Web of Science ®Google Scholar
• V Stambolic, JR Woodgett. Mitogen inactivation of glycogen synthase kinase-3b in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701–704.
   PubMed Web of Science ®Google Scholar
• WH Bullock, SR Magnuson, S Choi, DE Gunn, J Rudolph. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem 2002;2:915–938.
   PubMedGoogle Scholar
• OMEGA VUM. OpenEye Scientific Software Inc., Santa Fe, New Mexico, Jul., 2006.
   Google Scholar
• FRED VUM. 2006. OpenEye Scientific Software, (www.eyesopen.com), USA.
   Google Scholar
• R Bhat, Y Xue, S Berg, S Hellberg, M Ormo, Y Nilsson, AC Radesater, E Jerning, PO Markgren, T Borgegard, M Nylof, A Gimenez-Cassina, F Hernandez, JJ Lucas, J Diaz-Nido, J Avila. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937–45945.
   PubMed Web of Science ®Google Scholar
• MD Eldridge, CW Murray, TR Auton, GV Paolini, RP Mee. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997;11:425–445.
   PubMed Web of Science ®Google Scholar
• JH Cho, GV Johnson. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 2003;278:187–193.
   PubMed Web of Science ®Google Scholar
• A Martinez, M Alonso, A Castro, C Perez, FJ Moreno. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292–1299.
   PubMed Web of Science ®Google Scholar
• NV Carroll, RW Longley, JH Roe. The determination of glycogen in liver and muscle by use of anthrone reagent. J Biol Chem 1956;220:583–593.
   PubMed Web of Science ®Google Scholar
• MK Gilson, JA Given, BL Bush, JA McCammon. The statistical-thermodynamic basis for computation of binding affinities: A critical review. Biophys J 1997;72:1047–1069.
   PubMed Web of Science ®Google Scholar
• M Kontoyianni, LM McClellan, GS Sokol. Evaluation of docking performance: Comparative data on docking algorithms. J Med Chem 2004;47:558–565.
   PubMed Web of Science ®Google Scholar
• C Bissantz, G Folkers, D Rognan. Protein-based virtual screening of chemical databases: Evaluation of different docking/scoring combinations. J Med Chem 2000;43:4759–4767.
   PubMed Web of Science ®Google Scholar
• GP Vigers, JP Rizzi. Multiple active site corrections for docking and virtual screening. J Med Chem 2004;47:80–89.
   PubMed Web of Science ®Google Scholar
• DL Nelson, MM Cox. Carbohydrate biosynthesis. In: Lehninger principles of biochemistry. 3rd ed. New York: Worth Publishers; 1999. p 735–739.
   Google Scholar
• K Shojania, BE Koehler, T Elliott. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999;26:195–196.
   PubMed Web of Science ®Google Scholar